Our pipeline is focused on innovative therapeutic modalities and rationale combination treatment paradigms targeting difficult-to-treat cancers:
Development of the next-generation pipeline based on the latest science that addresses resistance mechanisms to Immune Checkpoint Inhibitors (ICIs)
Transformative clinical research that utilizes innovative study designs and novel biomarkers
Drug development to control lineage-dependent cancers with low sensitivity to existing therapies
Strengthen and optimize the collaboration between Clinical Development and the Eisai Discovery units
Exploration of biomarker-based tumor agnostic strategies
Harnessing immunoncology and understanding the tumor microenvironment in the pathogenesis of cancer